Skip to content

    Glenmark Pharmaceuticals Q4 FY26 earnings call

    GLENMARK
    Healthcare·1 Jun 2026
    Management Summary

    Glenmark Pharmaceuticals reported a strong Q4 and FY26, with consolidated revenue growing 15.8% and 27.5% YoY respectively. Key achievements include a significant licensing deal for ISB 2001, achieving a gross debt-free balance sheet, and robust growth in global brands like RYALTRIS. While the U.S. market faced temporary headwinds in Q4, the company anticipates strong growth in FY27 driven by new product launches and strategic investments across key markets.

    Highlights

    5
    • Consolidated revenue for FY26 grew 27.5% YoY to INR 169,825 million, demonstrating strong overall performance.

    • Q4 FY26 consolidated revenue grew 15.8% YoY to INR 37,706 million, indicating robust quarterly momentum.

    • Secured a landmark licensing deal with AbbVie for ISB 2001, including a USD 700 million upfront payment and a total potential deal value of USD 1.925 billion, validating the IGI BEAT platform.

    • Achieved gross debt-free status by the end of FY26, maintaining a healthy cash position of INR 1,200 crores.

    • RYALTRIS recorded over $100 million in sales last year with approximately 50% secondary sales growth, highlighting strong global brand traction.

    Concerns

    3
    • Q4 U.S. market performance was impacted by the timing of key product approvals and supply chain disruptions, leading to lower absorption of fixed costs.

    • India's diabetes segment has been lagging behind the market due to generic competition for remogliflozin and teneligliptin.

    • Receivables increased due to stopping pre-collections, delayed MEA region collections (war situation), and currency translation effects.

    Key financials

    Metrics

    7

    Periods

    3

    Headline

    5
    • Consolidated Revenue
      37,706 Mn
      YoY+15.8%
    • India Formulation Revenue
      10,201 Mn
      YoY+8.2%
    • North America Revenue
      9,248 Mn
      YoY+29.4%
    • Europe Revenue
      8,907 Mn
      YoY+21.4%
    • Emerging Markets Revenue
      8,979 Mn
      YoY+13.7%

    Q4 FY26

    1
    • R&D Spend
      ₹225 Cr

    FY26

    1
    • Consolidated Revenue
      1,69,825 Mn
      YoY+27.5%

    Capital allocation

    6
    high confidence
    CategoryHeadline
    Capex

    ₹900 crores

    Debt

    Gross ₹0 crores

    M&A

    ISB 2001 (AbbVie)

    Other · signed · Consideration ₹NaN (cash)

    M&A

    Trastuzumab Rezetecan (Hengrui Pharma)

    Other · signed

    M&A

    Aumolertinib (Hansoh Pharma)

    Other · signed

    Guidance & targets

    15
    CategoryTargetPriority
    Revenue
    Consolidated Revenue
    INR 17,000 crores to INR 18,000 crores
    High
    Profitability
    EBITDA Margin
    21% to 22%
    High
    R&D Spend
    R&D Spend as % of Sales
    8%
    High
    Working Capital
    Net Working Capital Days
    115 to 120 days
    High
    Capex
    Total Capex
    INR 900 crores
    High
    Product Growth
    RYALTRIS Sales Growth
    30%+
    High
    Market Growth
    India Formulation Business Growth
    15%+
    High
    Market Growth
    Europe Business Growth
    high single digit
    Medium
    Product Launches
    U.S. Respiratory Product Launches
    2 to 3 products
    High
    Product Launches
    European Respiratory Product Launches
    2 to 3 additional products
    High
    Product Contribution
    TEVIMBRA and BRUKINSA Contribution
    meaningfully contribute
    Medium
    Pipeline Development
    ISB-2301 IND Submission
    intended
    High
    Pipeline Development
    Trastuzumab Rezetecan MA Applications
    expected to begin
    High
    Product Launch
    Aumolertinib First Commercial Launch
    anticipated
    High
    Product Launch
    QiNHAYO First Commercial Launch
    expected
    High

    What to watch in Q1 FY27

    5

    U.S. Fluticasone MDI & other Respiratory Launches Traction

    Q1 FY27 onwards
    CurrentLimited impact in Q4 FY26 due to late launch and supply chain issues.
    TargetFull traction and meaningful contribution to U.S. revenue.

    Why it matters

    The U.S. business was a drag for 4 years, and these launches are key to its revival and achieving the ambitious FY27 revenue guidance.

    U.S. sale, which we targeted should have been much higher in Q4, which obviously will got spilled over because of this last movement supply chain and go to the market issues in U.S., which will obviously so this year, we'll see💬 a full traction of the Fluticasone Nasal Spray Flovent and other launches in U.S.

    Risks & concerns

    4
    RiskSeverity

    U.S. market performance impacted by timing of key product approvals and supply chain disruptions

    Lower absorption of fixed costs in Q4 FY26 due to late product approvals and supply chain issues.Management acknowledged

    medium

    India diabetes segment lagging due to generic competition

    Remogliflozin and teneligliptin struggled due to generic competition, making diabetes the only lagging segment in India.Analyst acknowledged

    medium

    Increased receivables

    Due to stopping pre-collections, delayed MEA region collections (war situation), and currency translation.Analyst acknowledged

    medium

    Geopolitical environment and supply chain volatility

    Impacted core operating margin due to higher distribution expenses linked to current geopolitical and supply chain environment in Q4.Management acknowledged

    medium

    Q&A highlights

    8

    “Yes. But by the time the product gets to the market and by the time you commercialize, right, March is pretty much... There was a supply chain because by the time we took the product to U.S. market because of the disruptions in the supply chain thing. So we could not really achieve the sales -- much of the sales in that quarter. And therefore, that as I mentioned, there was a fixed cost absorption issue.”

    Clarifies why a key product approval in the U.S. did not immediately boost Q4 results, attributing it to late-quarter launch and supply chain issues, setting expectations for FY27.

    asked by Damayanti Kerai

    3 min read7 chapters

    Detailed Narrative

    01

    Robust Financial Performance in FY26 and Q4

    Glenmark Pharmaceuticals Limited delivered a strong financial performance, with consolidated revenue for Q4 FY26 reaching INR 37,706 million, marking a 15.8% year-on-year growth compared to INR 32,562 million in the prior year. For the full fiscal year 2026, the company's consolidated revenue surged by 27.5% to INR 169,825 million, up from INR 133,217 million in FY25, reflecting broad-based growth across its key markets.

    02

    Landmark IGI Licensing Deal and Pipeline Advancement

    A significant highlight of FY26 was IGI's landmark licensing deal with AbbVie for ISB 2001, which included a USD 700 million upfront payment and a total potential deal value of USD 1.925 billion, along with tiered double-digit royalties. This transaction validates IGI's proprietary BEAT platform. The company is also advancing its broader IGI pipeline, having selected a clinical candidate for ISB-2301 with IND submission intended by the end of calendar year 2026.

    03

    Strategic Expansion in Oncology and Global Brands

    Glenmark accelerated its oncology business expansion in India and Emerging Markets through in-licensing commercial rights for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma. The global brand RYALTRIS continued its strong momentum, recording over $100 million in sales last year with approximately 50% plus secondary sales growth across its commercial markets. RYALTRIS is now commercialized in 55 markets and is expected to launch in 8-10 additional markets, including Brazil, in the coming quarters.

    04

    U.S. Market Revival and Respiratory Franchise Growth

    The U.S. business, which had been a drag for the past four years, is poised for significant growth in FY27. This is driven by the first ANDA approval for Fluticasone MDI (generic to FloVent 44mcg) with CGT designation and 180-day exclusivity, and the planned launch of 2-3 additional respiratory products in FY27. The Monroe facility also received VAI classification from the U.S. FDA in November 2025, enabling a restart of commercial manufacturing and supporting future growth in injectables.

    05

    India Business Outperformance and New Product Launches

    The India formulation business delivered a strong performance, growing 13.5% for the full year and 12.3% in Q4, significantly outpacing the IPM growth of 9% and 10.1% respectively. This growth was fueled by new launches such as TEVIMBRA, BRUKINSA, NEBZMART GFB nebulizer (world's first triple neb for COPD), and GLIPIQ (semaglutide vials/injection for diabetes). The GLIPIQ launch is expected to revitalize the previously lagging diabetes segment, with growth anticipated from Q1 FY27 onwards.

    06

    Robust Balance Sheet and Disciplined Capital Allocation

    Glenmark achieved a gross debt-free status by the end of FY26, maintaining a healthy cash position of INR 1,200 crores. The company plans disciplined capital allocation, with R&D spend maintained at 8% of sales and total capex normalizing to around INR 900 crores from FY27 onwards. This strategy focuses on strategic investments in core businesses, innovative pipeline, and maintaining working capital efficiencies to address geopolitical and supply chain uncertainties.

    07

    Optimistic FY27 Outlook with Clear Targets

    Management provided an optimistic outlook for FY27, targeting consolidated revenue between INR 17,000 crores and INR 18,000 crores, and an EBITDA margin of 21% to 22%. This growth is expected to be driven by new product launches, strategic investments and expansion in India and Emerging Markets, and the anticipated turnaround and strong performance of the U.S. business, which will see full traction from new respiratory launches.

    This is an AI-generated summary of a publicly available earnings call transcript.